Literature DB >> 28670957

XPNPEP2 is overexpressed in cervical cancer and promotes cervical cancer metastasis.

Teng Cheng1, Rui Wei1, Guiying Jiang1, Ying Zhou1, Mengqin Lv1, Yun Dai1, Yuan Yuan1, Danfeng Luo1, Ding Ma1, Fei Li1, Ling Xi1.   

Abstract

XPNPEP2 is a proline hydrolytic enzyme that hydrolyzes several biologically active peptides and causes a loss of substrate activity. However, its function in cancer is still unknown. Our study showed that XPNPEP2 expression was significantly upregulated in cervical cancer tissues compared with normal cervical tissues and cervical intraepithelial neoplasm tissues. Statistical analysis showed that XPNPEP2 expression was associated with the International Federation of Gynecology and Obstetrics stage and lymph node metastasis. Overexpression of XPNPEP2 in SiHa and HeLa cells promoted cell invasion and migration without affecting cell proliferation and apoptosis. Mechanistically, we found that XPNPEP2 facilitated cervical cancer cell invasion and migration by inducing epithelial-mesenchymal transition. Furthermore, we demonstrated that XPNPEP2 had significant effects on the metastasis of xenografted tumors in vivo. Collectively, our findings identify the novel function of XPNPEP2 in the metastasis of cervical cancer and suggest that XPNPEP2 could be a novel potential therapeutic target for the treatment of cervical cancer.

Entities:  

Keywords:  XPNPEP2; cervical cancer; epithelial–mesenchymal transition; metastasis

Mesh:

Substances:

Year:  2017        PMID: 28670957     DOI: 10.1177/1010428317717122

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.

Authors:  Kaan Oktay; Ashlie Santaliz-Casiano; Meera Patel; Natascia Marino; Anna Maria V Storniolo; Hamdi Torun; Burak Acar; Zeynep Madak Erdogan
Journal:  Horm Cancer       Date:  2019-12-19       Impact factor: 3.869

2.  Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3.

Authors:  Jiahua Zhou; Yeye Yi; Congjun Wang; Cheng Su; Yige Luo
Journal:  Oncol Lett       Date:  2019-08-01       Impact factor: 2.967

3.  XPNPEP2 is associated with lymph node metastasis in prostate cancer patients.

Authors:  Fei Li; Yun Dai; Hao Xu; Kecheng Huang; Ying Zhou; Danfeng Luo; Ding Ma; Ling Xi; Mengqin Lv; Xiangyi Ma
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379

4.  Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus.

Authors:  Xiang-Ming Wang; Yang Lu; Yi-Meng Song; Jun Dong; Ruo-Yan Li; Guo-Liang Wang; Xu Wang; Shu-Dong Zhang; Zhou-Huan Dong; Min Lu; Shi-Yu Wang; Li-Yuan Ge; Guang-Da Luo; Run-Zhuo Ma; Steve George Rozen; Fan Bai; Di Wu; Lu-Lin Ma
Journal:  Nat Commun       Date:  2020-02-06       Impact factor: 14.919

5.  TMTP1-modified Indocyanine Green-loaded Polymeric Micelles for Targeted Imaging of Cervical Cancer and Metastasis Sentinel Lymph Node in vivo.

Authors:  Rui Wei; Guiying Jiang; MengQin Lv; Songwei Tan; Xueqian Wang; Ying Zhou; Teng Cheng; Xueqin Gao; Xi Chen; Wei Wang; Chenming Zou; Fei Li; Xiangyi Ma; Junbo Hu; Ding Ma; Danfeng Luo; Ling Xi
Journal:  Theranostics       Date:  2019-09-25       Impact factor: 11.556

6.  Genomic and transcriptomic characterization of the human glioblastoma cell line AHOL1.

Authors:  W A S Ferreira; C K N Amorim; R R Burbano; R A R Villacis; F A Marchi; T S Medina; M M C de Lima; E H C de Oliveira
Journal:  Braz J Med Biol Res       Date:  2021-01-15       Impact factor: 2.590

7.  TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy.

Authors:  Guiying Jiang; Xueqian Wang; Ying Zhou; Chenming Zou; Ling Wang; Wei Wang; Danya Zhang; Hanjie Xu; Jie Li; Fei Li; Danfeng Luo; Xiangyi Ma; Ding Ma; Songwei Tan; Rui Wei; Ling Xi
Journal:  Int J Nanomedicine       Date:  2021-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.